The transaction forms part of AngioDynamics’ strategy to expand its oncology portfolio. BioSentry is a biopsy sealant system developed to prevent pneumothorax in CT-guided percutaneous lung biopsy procedures.
BioSentry delivers a self-expanding hydrogel plug into the pleural space after a biopsy. This plug creates an airtight seal that closes pleural puncture and prevents leakage, thereby minimising the risk of pneumothorax.
Data from a clinical trial conducted in 2010 in 339 patients across 15 sites indicated an 85% clinical success rate with the BioSentry system, compared to 69% in the control group.
The device secured the US Food and Drug Administration (FDA) approval in 2012, and was commercially launched in 2013. It also obtained the European CE-Mark approval.
AngioDynamics president and CEO Jim Clemmer said: “The addition of the BioSentry technology to our oncology portfolio is the type of strategic and thoughtful acquisition that aligns with our plans to deliver safer, clinically relevant, and economically favourable solutions that improve patient outcomes.
“By expanding our offerings in the oncology discipline, we are creating an opportunity to serve patients who may also benefit from our core products earlier in their disease state.”
Apart from the BioSentry technology, Surgical Specialties’ 12-person commercial organisation will also become part of AngioDynamics’ Oncology business.
AngioDynamics also reported that the Northern District of New York has rejected a motion by CR Bard to dismiss the company’s lawsuit over tip location systems.
The lawsuit alleged that Bard’s move to link the tip location systems with its peripherally inserted central catheters (PICCs) offers a dominant position in the associated market.
This is because customers wanting to purchase Bard’s systems must also buy its line of PICCs, thereby hindering sales of AngioDynamics’ BioFlo PICCs.